Mirogabalin: general
Mirogabalin is a prescription painkiller for nerve pain, developed by the Japanese company Daiichi Sankyo. In 2019 the company “announced the receipt of marketing approval in Japan” under the brand name Tarlige, “for the treatment of peripheral neuropathic pain”.[1] It belongs to the same family as gabapentin and pregabalin (the gabapentinoids), and it is not approved in the United States or Europe; the legal section covers what that means. Outside those markets it is sold as a powder, and the experiences section collects what readers report. This page is a summary of what the research says. It is not medical advice and it gives no amounts.
Side effects in the trials
The largest safety data come from two placebo-controlled trials in Asian patients with diabetic nerve pain or pain after shingles. In the pooled results, “Treatment-emergent adverse events included somnolence” and dizziness, both more common at higher amounts, and swelling of the legs led some patients to stop.[2] The authors also found that sex, older age and lower body weight “may influence the safety of mirogabalin particularly regarding the incidence of somnolence and dizziness”.[2] Sleepiness and dizziness matter for driving and for falls, especially in older people.
Abuse potential
This is one compound where there is direct human data. The developer ran the study regulators ask for, in “recreational polydrug users” who could tell an active drug from a placebo.[3] “At therapeutic doses, mirogabalin Drug Liking E max did not differ significantly from placebo”, and it was liked less than diazepam or pregabalin.[3] At amounts several times higher than that, the picture changed: “mirogabalin had significantly higher Drug Liking E max than placebo, but lower E max than pregabalin”.[3] So it is not free of abuse potential; it was rated as somewhat lower than pregabalin's. Two things limit this result. Each participant took single doses, so it says nothing about tolerance or dependence over weeks. And the study was paid for by the company that makes the drug: several authors “are employees of Daiichi Sankyo”.[3]
Breathing, and mixing with depressants
The most serious risk of this drug family is slowed breathing. The US Food and Drug Administration warned in 2019 that gabapentin and pregabalin can cause serious breathing problems in people with risk factors, and that “These include the use of opioid pain medicines and other drugs that depress the central nervous system”.[4] “The elderly are also at higher risk.”[4] The same notice said gabapentinoid use “has been growing for prescribed medical use as well as misuse and abuse”.[4] That warning names gabapentin and pregabalin, not mirogabalin, which was never reviewed for the US market; we apply it here because mirogabalin acts at the same target.
There is some evidence that mirogabalin may differ. A study of Japanese adverse-event reports found that for respiratory depression “a signal was detected with pregabalin use but not with mirogabalin use”.[5] Report databases like that one count what doctors chose to report, so the absence of a signal is weak evidence of safety, and mirogabalin has been on the market for far less time. The cautious reading is to treat it like its relatives: combining it with opioids, benzodiazepines, alcohol or other sedatives can deepen sedation and slow breathing.
Other reported harms
A 2026 analysis of the same Japanese database said mirogabalin's “post-marketing safety profile remains insufficiently characterized” and flagged several possible new signals, including “toxic encephalopathy”, a confused, poisoned state of the brain.[6] Those are signals for investigation, not established effects. One case report describes an older woman with Lewy body dementia who “developed hallucinations and delusional misidentification of places and persons immediately after receiving a prescription of mirogabalin”, which cleared when it was stopped.[7]
Stopping
For gabapentin and pregabalin, the FDA's advice is that they “should be tapered prior to discontinuation”, not stopped abruptly.[4] Our PubMed search on 2026-11-21 returned 31 records on mirogabalin and abuse, dependence, withdrawal, misuse, overdose or respiratory depression, and we found no study of what happens when people stop mirogabalin after long use.[8] That is a gap in what our search found, not evidence that withdrawal does not happen; its relatives make it a reasonable thing to expect.
What is not known
Every trial above was in patients with nerve pain, taking a pharmacy product under supervision. We found no study of non-medical use, of long-term use outside a trial, or of what a powder sold under the name actually contains.[8]
References
- Daiichi Sankyo Announces Marketing Approval in Japan of 'Tarlige Tablets' for Pain Treatment (press release, 8 January 2019) — Daiichi Sankyo
- Safety and Efficacy of Mirogabalin for Peripheral Neuropathic Pain: Pooled Analysis of Two Pivotal Phase III Studies (Kato et al., Clinical Therapeutics, 2021) — PubMed (US National Library of Medicine)
- Abuse potential of mirogabalin in recreational polydrug users (Mendell et al., Therapeutic Advances in Drug Safety, 2019) — PubMed (US National Library of Medicine)
- FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR), Drug Safety Communication of 12-19-2019, Wayback capture of 7 March 2026 — US Food and Drug Administration
- Occurrence of somnolence and respiratory depression induced by pregabalin and mirogabalin use and the influence of opioid treatment using the Japanese adverse drug event report database (Kato, Koseki and Kondo, Pharmazie, 2024) — PubMed (US National Library of Medicine)
- Post-marketing safety evaluation of mirogabalin using the JADER database (Sun et al., Frontiers in Pharmacology, 2026) — PubMed (US National Library of Medicine)
- A case of dementia with Lewy bodies with psychosis induced by low-dose gabapentinoids (Kanemoto et al., BMC Psychiatry, 2025) — PubMed (US National Library of Medicine)
- PubMed search for mirogabalin AND (abuse OR dependence OR withdrawal OR misuse OR overdose OR respiratory depression) (run 2026-11-21: 31 records; one human abuse-potential study, pharmacovigilance analyses and case reports; no study of withdrawal or of non-medical use) — PubMed (US National Library of Medicine)
Comments
Sign in to join the conversation.
No comments yet.